Is Tucatinib covered by medical insurance? Can it reduce the burden?

Up to now, Tucatinib (Tucatinib) has not been officially launched in mainland China, so it has not yet been included in the national medical insurance directory. This means that domestic patients cannot reduce the burden of purchasing drugs through medical insurance reimbursement, and can only rely on purchasing drugs at their own expense or seeking overseas drug channels. As a new targeted drug for the treatment of HER2 positive breast cancer, tucatinib has been approved internationally by the FDA and EMA and has shown good therapeutic prospects, but its domestic introduction is still in the advancement stage.

Since it has not entered the Chinese market, the original drug of tucatinib cannot be obtained through domestic hospitals and pharmacies. Currently in the European market, the price of original tucatinib in 150mg*84 tablet format is as high as more than 40,000 yuan per box. The price is very expensive, making it difficult for most patients to afford it in the long term. In the absence of medical insurance coverage, patients bear all drug costs themselves, which puts greater financial pressure.

However, for patients with limited financial means, overseas generic drugs provide a lower-cost option. For example, the generic version of tucatinib produced by a Lao pharmaceutical factory in 150mg*60 tablets sells for about more than 2,000 yuan per box. This generic drug is basically the same as the original drug in terms of composition and mechanism, has similar efficacy, and is cost-effective. It has been used to replace the original drug for treatment in some patients.

To sum up, since the original drug tucatinib has not yet been launched in China and cannot be included in the medical insurance system, patients currently need to consider purchasing it at their own expense or obtaining a generic version through regular overseas channels. It is recommended that patients communicate with professional oncologists before taking medication, and choose appropriate drug sources based on their own conditions and economic conditions. At the same time, they should pay attention to the formality and safety of drug sources to avoid the risks of using fake or inferior drugs.

Reference materials:https://www.drugs.com/

xa0